Literature DB >> 15618724

CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites.

Akio Suzuki1, Izumi Iida, Mitsuyo Hirota, Masayuki Akimoto, Shohei Higuchi, Toshio Suwa, Masayoshi Tani, Takashi Ishizaki, Kan Chiba.   

Abstract

To clarify whether CYP2C19 is involved in the overall metabolism of clarithromycin (CAM) or not, in vitro studies using human liver microsomes and recombinant CYPs were performed by an approach based on the disappearance rate of parent compound from the incubation mixture. In addition, the results of disappearance rate were compared with those obtained from the formation rates of the major metabolites of CAM, 14-(R)-hydroxy-CAM and N-demethyl-CAM. The intrinsic clearance (CL(int)) values determined from the disappearance of CAM in nine different human liver microsomes were highly correlated with the testosterone 6beta-hydroxylation activity (r=0.957, p<0.001). The CL(int) of CAM was markedly reduced by selective inhibitors of CYP3A4 (ketoconazole and troleandomycin) and by polyclonal antibodies raised against CYP3A4/5 in human liver microsomes. Among the 11 isoforms of recombinant human CYP, only CYP3A4 revealed the metabolic activity for the disappearance of CAM. These results were fairly consistent with those obtained from the conventional approach based on the formation of major metabolites of CAM. Comparison of the kinetic parameters estimated from the disappearance rate of CAM and the formation rates of 14-(R)-hydroxy-CAM and N-demethyl-CAM indicates that N-demethylation and 14-(R)-hydroxylation account for 65% of CL(int) derived from the disappearance of CAM in human liver microsomes. The findings suggest that CYP3A4 plays a predominant role in the overall metabolic clearance of CAM as well as in the formation of 14-(R)-hydroxy-CAM and N-demethyl-CAM. CYP2C19 does not appear to be involved in the overall metabolism of CAM at least in human liver microsomes. A combination of the disappearance rate of a parent compound and the formation rate of metabolites appears to be a useful approach for estimating the percentage contribution of the formation of metabolites to the overall metabolic clearance of a parent compound in vitro.

Entities:  

Year:  2003        PMID: 15618724     DOI: 10.2133/dmpk.18.104

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  6 in total

1.  Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Authors:  Sara K Quinney; Xin Zhang; Aroonrut Lucksiri; J Christopher Gorski; Lang Li; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2009-11-02       Impact factor: 3.922

2.  Contributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability.

Authors:  Xiaoyu Fan; Hongmin Li; Xinxin Ding; Qing-Yu Zhang
Journal:  Drug Metab Dispos       Date:  2019-04-30       Impact factor: 3.922

3.  Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.

Authors:  Khaled Abduljalil; Martina Kinzig; Jürgen Bulitta; Stefan Horkovics-Kovats; Fritz Sörgel; Michael Rodamer; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

4.  In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.

Authors:  Mitsuhiro Nishihara; Hitomi Yamasaki; Richard Czerniak; Helen Jenkins
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.441

5.  Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.

Authors:  Seiichiro Komatsu; Keisuke Miyazawa; Shota Moriya; Akiko Takase; Munekazu Naito; Masato Inazu; Norio Kohno; Masahiro Itoh; Akio Tomoda
Journal:  Int J Oncol       Date:  2011-12-23       Impact factor: 5.650

6.  Comparable Intestinal and Hepatic First-Pass Effect of YL-IPA08 on the Bioavailability and Effective Brain Exposure, a Rapid Anti-PTSD and Anti-Depression Compound.

Authors:  You Gao; Chunmiao Yang; Lingchao Wang; Yanan Xiang; Wenpeng Zhang; Yunfeng Li; Xiaomei Zhuang
Journal:  Front Pharmacol       Date:  2020-11-27       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.